These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 35853681)
1. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study. Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681 [TBL] [Abstract][Full Text] [Related]
2. Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT). Janžič U; Turnšek N; Dediu M; Donev IS; Lupu R; Teodorescu G; Ciuleanu TE; Pluzanski A Curr Oncol; 2022 Aug; 29(8):5833-5845. PubMed ID: 36005198 [TBL] [Abstract][Full Text] [Related]
3. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357 [TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932 [TBL] [Abstract][Full Text] [Related]
5. Study of patient characteristics, treatment patterns, Winfree KB; Sheffield KM; Cui ZL; Sugihara T; Feliciano J Curr Med Res Opin; 2022 Jan; 38(1):91-99. PubMed ID: 34544302 [TBL] [Abstract][Full Text] [Related]
6. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
7. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec. Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073 [TBL] [Abstract][Full Text] [Related]
8. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Addeo A; Hochmair M; Janzic U; Dudnik E; Charpidou A; Płużański A; Ciuleanu T; Donev IS; Elbaz J; Aarøe J; Ott R; Peled N Ther Adv Med Oncol; 2021; 13():17588359211059874. PubMed ID: 35173817 [TBL] [Abstract][Full Text] [Related]
9. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Lu S; Shih JY; Jang TW; Liam CK; Yu Y Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
11. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963 [TBL] [Abstract][Full Text] [Related]
12. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer. Walia M; Singhal MK; Kamle MS Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193 [TBL] [Abstract][Full Text] [Related]
13. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE Thorac Cancer; 2022 Jul; 13(13):1888-1897. PubMed ID: 35633141 [TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting. Apple J; Shenolikar R; De Silva K; Sun P; Spira A Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437 [TBL] [Abstract][Full Text] [Related]
18. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468 [TBL] [Abstract][Full Text] [Related]
19. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
20. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study. Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]